What is Synapticure?
Synapticure operates at the intersection of personalized medicine and digital health, specifically targeting the complex needs of the ALS community. Founded by individuals directly impacted by the disease and supported by leading clinicians, the firm provides a comprehensive platform that brings specialized care directly to the patient's home. By integrating clinical expertise with a scalable digital infrastructure, Synapticure addresses the systemic inefficiencies in traditional care models, ensuring that patients receive timely, high-quality support. Its market position is defined by a commitment to transforming the patient experience, moving away from fragmented care toward a cohesive, technology-driven ecosystem that prioritizes long-term health outcomes and accessibility.
How much funding has Synapticure raised?
Synapticure has raised a total of $31M across 2 funding rounds:
Angel/Seed
$6M
Series A
$25M
Angel/Seed (2022): $6M with participation from GV, Martin Ventures, Ben and Divya Silbermann, Rohan Seth, Lifeforce Capital Gp I, Joe Kraus, Ron Conway, Adam Koppel, Y Combinator, Gerald E. Bisbee, Jeff Huber, Byers Capital, and David Hodgson
Series A (2024): $25M led by GV, B Capital Group, RA Capital Management, and CVS Health
Key Investors in Synapticure
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
B Capital Group
B Capital is a global venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs and medical devices.
What's next for Synapticure?
With the successful closure of its latest financing round, Synapticure is set to expand its operational footprint and enhance its digital care delivery platform. The strategic focus will likely center on scaling its clinical network and deepening its integration with existing healthcare systems to ensure broader reach for ALS patients. As the company matures, the emphasis will shift toward optimizing its data-driven care protocols and potentially exploring new therapeutic support modules. By maintaining its focus on evidence-based outcomes, Synapticure is expected to solidify its role as a critical infrastructure provider in the specialized healthcare market, attracting further interest from institutional investors focused on the intersection of life sciences and enterprise technology.
See full Synapticure company page
